Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | GPR27 | Q9NS67 | 10/20 | 0.57 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | FLT4 | P35916 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | PCTP | Q9UKL6 | 2/20 | 0.48 |
| ▸ | STARD7 | Q9NQZ5 | 1/20 | 0.48 |
| ▸ | STARD10 | Q9Y365 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828148 | 0.90 | GAA (0.64) | GAAGPR27AVPR2MEN1KMT2A | |
| SCHEMBL4867851 | 0.90 | GAA (0.64) | GAAGPR27AVPR2MEN1KMT2A | |
| SCHEMBL4867847 | 0.90 | GAA (0.64) | GAAGPR27AVPR2MEN1KMT2A | |
| SCHEMBL4828151 | 0.90 | GAA (0.64) | GAAGPR27AVPR2MEN1KMT2A | |
| SCHEMBL4828226 | 0.86 | GAA (0.67) | GAAGPR27AVPR2MEN1KMT2A | |
| SCHEMBL4828227 | 0.86 | GAA (0.67) | GAAGPR27AVPR2MEN1KMT2A | |
| SCHEMBL4825244 | 0.85 | GAA (0.57) | GAAGPR27AVPR2MEN1KMT2A | |
| SCHEMBL4826473 | 0.85 | GAA (0.65) | GAAGPR27AVPR2MEN1KMT2A | |
| SCHEMBL4826470 | 0.85 | GAA (0.65) | GAAGPR27AVPR2MEN1KMT2A | |
| SCHEMBL4826202 | 0.80 | GAA (0.64) | GAAGPR27AVPR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6403644-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | claimed |
| EP-0757037-A2 | Sulfonylamino acid derivatives as metalloproteinase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-05 | — | — | EP | claimed |
| US-7335686-B2 | Method and composition for treating osteoporosis | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-02-26 | — | — | US | disclosed |
| EP-1678124-A1 | NOVEL MOLECULES TO DEVELOP DRUG FOR THE TREATMENT OF OSTEOPOROSIS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005037774-A1 | NOVEL MOLECULES TO DEVELOP DRUG FOR THE TREATMENT OF OSTEOPOROSIS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-04-28 | — | — | WO | disclosed |
| US-20050085537-A1 | Method and composition for treating osteoporosis | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2005-04-21 | — | — | US | disclosed |
| US-6403644-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-6177466-B1 | Sulfonylamino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| EP-0757037-A2 | Sulfonylamino acid derivatives as metalloproteinase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085537-A1 | Method and composition for treating osteoporosis | SOST, CALCR, MSR1 | GAA 4390/4885GPR27 306/4885AVPR2 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.